Bruker (BRKR) fundamentals: P/E, valuation, undervalued?
Bruker · Health Care · ref. ETF XLV · price $59.25
In short — Bruker trades at —× earnings (P/E), 24.6× forward, with a net margin of -2.0 % and revenue growth of +5 %. Read: Not (yet) profitable (valued on growth, not earnings).
Is Bruker stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$59.25+77.1% over range
Aug 28, 25low $29.35 · high $64.34Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
57% recommend buying · 7 analysts
Valuation : Not (yet) profitable — valued on growth, not earnings
Valuation
—
P/E (price/earnings)
24.6
Forward P/E
—
PEG
3.8
Price/book (P/B)
$9.0B
Market cap
-0.73
EPS
Profitability & growth
-2.0 %
Net margin
+5 %
Revenue growth
—
Earnings growth
$1.9B
Total debt
Bruker income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2022 | $2.5B | $297M | 11.7 % |
| 2023 | $3.0B | $427M | 14.4 % |
| 2024 | $3.4B | $113M | 3.4 % |
| 2025 | $3.4B | $-23M | -0.7 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Bruker's P/E and is the stock undervalued? What's a good P/E?
Bruker's P/E is — (forward 24.6). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "Not (yet) profitable".
Is Bruker profitable?
Bruker has a net margin of -2.0 % (EPS -0.73). The company is not (yet) profitable.
Is BRKR stock expensive?
Our read: "Not (yet) profitable" — valued on growth, not earnings. Cross-check with growth and sector.
💬 A question about Bruker? The JPI assistant answers using our backtest data.